A stratified, randomized, open-label, multi-center comparative 2-arm trial of PK [pharmacokinetic], PD [pharmacodynamic], and safety of zoledronic acid infusions administered monthly vs. every 3-month, in multiple myeloma patients with malignant bone lesions, and breast cancer patients with bone metastasis, who have received 9-12 doses of zoledronic acid over the prior year.

Trial Profile

A stratified, randomized, open-label, multi-center comparative 2-arm trial of PK [pharmacokinetic], PD [pharmacodynamic], and safety of zoledronic acid infusions administered monthly vs. every 3-month, in multiple myeloma patients with malignant bone lesions, and breast cancer patients with bone metastasis, who have received 9-12 doses of zoledronic acid over the prior year.

Completed
Phase of Trial: Phase I

Latest Information Update: 30 Oct 2014

At a glance

  • Drugs Zoledronic acid (Primary)
  • Indications Breast cancer; Multiple myeloma
  • Focus Pharmacokinetics
  • Sponsors Novartis
  • Most Recent Events

    • 02 Mar 2012 Actual end date (Nov 2009) added as reported by ClinicalTrials.gov.
    • 02 Mar 2012 Actual patient number is 18 according to ClinicalTrials.gov.
    • 02 Mar 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top